From February 27th to March 3rd, ZSHK accompanied a delegation from the China Pharmaceutical Innovation and Research Development Association (PhIRDA) on a visit to Hong Kong and Singapore. They also held a reception dinner in Hong Kong, where they engaged in fruitful discussions with colleagues from the pharmaceutical industry in both regions.

On March 14th and 15th, ZSHK was invited to attend the Hong Kong Bio-Med Innotech Association's 2023 Spring banquet and the Shenzhen Pingshan-Hong Kong Biotechnology Cooperation Matchmaking Conference. Dr. Li Ming, CEO of ZSHK, was invited to share his experiences in cross-border exchanges with the attendees.

From March 29th to 31st, ZSHK attended the 7th China BioMed Innovation and Investment Conference (CBIIC), where they had full communication and established friendly connections with industry colleagues, promoting research and development collaborations.

On April 14th and 15th, Dr. Xing Guozhen, General Manager of ZSHK-Anling (Suzhou), was invited to participate in the inaugural China Conference on R&D and Innovation of Drugs and Equipment for Diabetes and Metabolic Diseases. He delivered a keynote speech and participated in discussions on "Preclinical Pharmacokinetics and Pharmacodynamics Evaluation".

On May 17, the ZSHK was invited to participate in the 3rd Asia Summit on Global Health, where they set up an exhibition booth to attract experts and from colleagues the global biopharmaceutical field discussions for and exchanges.

On June 2nd, Dr. Li Ming, CEO of ZSHK, was invited to attend the lecture on "Key Factors in the Early Evaluation of Chemical Drug Efficacy" at the University of Macau and delivered a keynote speech.

On June 7th, ZSHK was invited to attend the 55th Annual Dinner of the Hong Kong Association of Pharmaceutical Industries.

On June 8th, A wholly owned subsidiary of ZSHK--Anling Biomed (Shenzhen) Co., Ltd., successfully held the launch event for its GLP Center. The event included thematic presentations, roundtable discussions, and site visits, and was a great success.

From June 9th to 11th, A wholly owned subsidiary of ZSHK--Anling Biomed (Shenzhen) Co., Ltd. was invited to participate in the inaugural National Forum on Experimental Pathology and High-End Medical Device Innovation. Anling (Shenzhen) General Manager Jin Yi led the company's key technical personnel in extensive exchanges with industry experts.

From June 15th to 18th, A wholly owned subsidiary ofAnling Biomed (Shenzhen) participated in the Academic Conference on Drug Toxicology and Safety Evaluation of the Chinese Society of Toxicology and the Second Summit Forum of Biopharmaceutical Industry in the Guangdong-Hong Kong-Macao Greater Bay Area. They also set up an exhibition booth and engaged in in-depth exchanges with experts from various fields.

On June 18th, ZSHK was invited to attend the China DIA Annual Meeting and had an exhibition booth at the event. Dr. Li Ming, CEO of ZSHK, participated in a roundtable discussion on "Value Co-creation: upstream and downstream enterprises jointly build a Collaborative New Ecology for the Pharmaceutical Industry".